Seth A. Rudnick M.D.
Chairman and Scientific and Clinical Advisor,G1 Therapeutics, Inc.
|Age||Total Calculated Compensation||This person is connected to 105 board members in 12 different organizations across 20 different industries.|
See Board Relationships
Dr. Seth A. Rudnick, M.D., serves as the Chairman and Scientific and Clinical Advisor of G1 Therapeutics, Inc. since January 7, 2014. Dr. Rudnick has been the Chairman of Liquidia Technologies Inc. since March 11, 2008. He serves as the Chairman of ORTHOCON Inc, Drug Innovation Ventures at Emory (DRIVE) and Meryx Inc. He has been a Director of Liquidia Technologies, Inc. since 2006, Square 1 Financial Inc. since November 2012, Aralez Pharmaceuticals Inc. (Pozen Inc.) ...
79 T.W. Alexander DrivePhone: 919-213-9835
Research Triangle Park, North Carolina 27709
Board Members Memberships*
Chairman of the Board
Chairman and Scientific and Clinical Advisor
University of Pennsylvania
University of Virginia
Washington University, St. Louis
Annual Compensation*There is no Annual Compensation data available.
Stock Options*There is no Stock Options data available.
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.
|Paul V. Campanelli||Chief Executive Officer, President and Director|
Endo International plc
|Daniel N. Swisher Jr.||Chief Executive Officer, President and Director|
Sunesis Pharmaceuticals, Inc.
|Andrew Philip Witty||Chief Executive Officer and Executive Director|
|Kenneth C. Frazier||Chairman, Chief Executive Officer and President|
Merck & Co., Inc.
|Pascal Soriot||Chief Executive Officer, Executive Director and Member of Disclosure Committee|
|3.2M GBP||Compensation as of Fiscal Year 2015.|
Sponsored Financial Commentaries
Only a company representative may request an update for the company profile. Documentation will be required.